SANM is classified as an autoimmune-associated myopathy following abnormal production of anti-HMGCR autoantibodies after statin medications, different from well-established polymyositis/dermatomyositis-associated antibodies against aminoacyl-tRNA synthetases (ARS). Here, HMGCR is linked to polymyositis.